Brand | Abnova |
Product type | Primary antibodies |
Reactivity | Human |
Host species | Goat |
Applications | ELISA,IHC-P |
Brand: | Abnova |
Reference: | PAB6614 |
Product name: | PAX3 polyclonal antibody |
Product description: | Goat polyclonal antibody raised against synthetic peptide of PAX3. |
Gene id: | 5077 |
Gene name: | PAX3 |
Gene alias: | CDHS|HUP2|MGC120381|MGC120382|MGC120383|MGC120384|MGC134778|WS1 |
Gene description: | paired box 3 |
Immunogen: | A synthetic peptide corresponding to human PAX3. |
Immunogen sequence/protein sequence: | TTLAGAVPRMM-C |
Protein accession: | NP_000429.2;NP_0.39230.1;NP_852122;.1NP_852123.1;NP_852124.1;NP_852125.1;NP_852126.1 |
Form: | Liquid |
Concentration: | 0.5 mg/mL |
Recommend dilutions: | ELISA (1:64000) Immunohistochemistry (3 ug/mL) The optimal working dilution should be determined by the end user. |
Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
Product type: | Primary antibodies |
Host species: | Goat |
Antigen species / target species: | Human |
Specificity: | This antibody is expected to recognize all 7 reported human isoforms (as represented by NP_000429.2, NP_0.39230.1, NP_852122,.1 NP_852123.1, NP_852124.1, NP_852125.1 and NP_852126.1). |
Reactivity: | Human |
Application image: | ![]() |
Application image note: | PAX3 polyclonal antibody (Cat # PAB6614) (3 ug/mL) staining of paraffin embedded human esophagus. Microwaved antigen retrieval with Tris/EDTA buffer pH9, HRP-staining. |
Applications: | ELISA,IHC-P |
Shipping condition: | Dry Ice |
Publications: | Isolation of two isoforms of the PAX3 gene transcripts and their tissue-specific alternative expression in human adult tissues.Tsukamoto K, Nakamura Y, Niikawa N. Hum Genet. 1994 Mar;93(3):270-4. |